(Reuters) - The report on Tuesday of a powerful treatment for the new coronavirus brought skepticism along with optimism among U.S. doctors, who said the recent withdrawal of an influential COVID-19 study left them wanting to see more data. A pharmacist displays a box of Dexamethasone at the Erasme Hospital amid the coronavirus disease (COVID-19)…
5 min read WHEN THE JUSTICE Department released a trove of Epstein-related files on January 30 and then pulled down thousands of pages after redaction failures exposed victims’ identifying information and explicit material, I felt a familiar gut-drop. Once again, the people with the least power were being asked to pay twice—first for the abuse
You don't have permission to access "http://www.medpagetoday.com/obgyn/hrt/119940" on this server. Reference #18.5bf4d517.1771491743.1e0de1 https://errors.edgesuite.net/18.5bf4d517.1771491743.1e0de1
It’s the rare policy question that unites Republican Gov. Ron DeSantis of Florida and the Democratic-led Maryland government against President Donald Trump and Gov. Gavin Newsom of California: How should health insurers use AI? Regulating artificial intelligence, especially its use by health insurers, is becoming a politically divisive topic, and it’s scrambling traditional partisan lines.